Coverage
-
January 31, 2018
AbbVie Inc. on Tuesday asked an Illinois federal judge for a new trial in the second bellwether case over claims the drugmaker failed to warn consumers about risks accompanying its testosterone treatment AndroGel, calling the $140 million verdict fatally inconsistent.
4 other articles on this case.
View all »